Expert recommendations regarding the use of fecal calprotectin in daily clinical practice: statements of a taskforce process from the Hellenic Group for the Study of Inflammatory Bowel Disease (EOMIFNE)

Giorgos Bamias; Smaragdi Fessatou; Christina Kapizioni; Konstantina Kitsou; Gergios Kokkotis; Afroditi Kourti; Panagiotis Markopoulos; Elina Orfanoudaki; Spyridon Siakavellas; Maria Tzouvala

Authors Giorgos Bamias, Smaragdi Fessatou, Christina Kapizioni, Konstantina Kitsou, Gergios Kokkotis, Afroditi Kourti, Panagiotis Markopoulos, Elina Orfanoudaki, Spyridon Siakavellas, Maria Tzouvala.

Abstract

Fecal calprotectin (FC) has become an indispensable tool in everyday clinical practice for the diagnosis and management of inflammatory bowel disease (IBD). Nonetheless, specific and clear recommendations for its use are scarce. On behalf of the Hellenic Group for the Study of IBD (EOMIFNE), a group of experts have formulated 18 statements with the aim to provide evidence for the best use of FC and offer practical guidance in common clinical scenarios. Statements address issues for the proper application of FC measurement in the diagnostic workup of patients with gastrointestinal symptoms, and as a screening tool for the management of established IBD, including pediatric patients. Thus, the present manuscript aims to propose a standardized approach for the optimal use of FC in patient care, also taking into account non-medical concerns.

Keywords Fecal calprotectin, inflammatory bowel disease, EOMIFNE, guidelines

Ann Gastroenterol 2026; 39 (2): 161-173